**Name of journal:** ***World Journal of*** ***Gastroenterology***

**ESPS Manuscript NO: 24719**

**Manuscript Type: ORIGINAL ARTICLE**

***Retrospective Cohort Study***

**Genomic change in hepatitis B virus associated with development of hepatocellular carcinoma**

Lee DB *et al.* HBV Genomic change and HCC development

**Danbi Lee, Heather Lyu, Young-Hwa Chung, Jeong A Kim, Priya Mathews, Elizabeth Jaffee, Lei Zheng, Eunsil Yu, Young Joo Lee, Soo Hyung Ryu**

**Danbi Lee, Young-Hwa Chung, Jeong A Kim,** Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, South Korea

**Heather Lyu, Priya Mathews, Elizabeth Jaffee, Lei Zheng,** Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21218, United States

**Eunsil Yu,** Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, South Korea

**Young Joo Lee,** Department of Hepatobiliary Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, South Korea

**Soo Hyung Ryu,** Department of Internal Medicine, Inje University College of Medicine, Seoul Paik Hospital, Seoul 04551, South Korea

**Author contributions:** Lee D and Lyu H contributed equally to this work; Chung YH is a corresponding author; Lee D, Lyu H, Chung YH designed the study, provided collection and analyses of the data and wrote the manuscript; Kim JA, Mathews P and Ryu SH conducted the experimental work; Chung YH, Jaffee E and Zheng Lwere involved in editing the manuscript; Yu E and Lee YJ provided the collection of human material.

**Institutional review board statement:** The study was reviewed and approved by the Institutional Review Board of Asan Medical Center.

**Informed consent statement:** Waiver of Informed Consent for this study has been granted by the Institutional Review Board of Asan Medical Center due to demonstrated minimal risk.

**Conflict-of-interest statement:** All the authors have no conflict of interest related to the manuscript.

**Data sharing statement:** All the anonymous dataset is available on request from the corresponding author at yhchung@amc.seoul.kr

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Young-Hwa Chung, MD, PhD,** Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea. yhchung@amc.seoul.kr

**Telephone:** +82-2-30103184

**Fax:** +82-2-4760824

**Received:** February 2, 2016

**Peer-review started:** February 2, 2016

**First decision:** March 7, 2016

**Revised:** March 21, 2016

**Accepted:** April 7, 2016

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To determine the genomic changes in hepatitis B virus (HBV) and evaluate their role in the development of hepatocellular carcinoma (HCC) in patients chronically infected with genotype C HBV.

**METHODS:** Two hundred and forty chronic hepatitis B (CHB) patients were subjected and followed for a median of 105 mo. HCC was diagnosed in accordance with AASLD guidelines. The whole X, S, basal core promoter (BCP), and precore regions of HBV were sequenced using the direct sequencing method.

**RESULTS:** All of the subjects were infected with genotype C HBV. Out of 240 CHB patients, 25 (10%) had C1653T and 33 (14%) had T1753V mutation in X region; 157 (65%) had A1762T/G1764A mutations in BCP region, 50 (21%) had G1896A mutation in precore region and 67 (28%) had pre-S deletions. HCC occurred in 6 patients (3%). The prevalence of T1753V mutation was significantly higher in patients who developed HCC than in those without HCC. The cumulative occurrence rates of HCC were 5% and 19% at 10 and 15 years, respectively, in patients with T1753V mutant, which were significantly higher than 1% and 1% in those with wild type HBV (*P* < 0.001).

**CONCLUSION:** The presence of T1753V mutation in HBV X-gene significantly increases the risk of HCC development in patients chronically infected with genotype C HBV.

**Key words:** Hepatocellular carcinoma; Chronic hepatitis B; Genomic change; Hepatitis B virus; Genotype C

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** In the present study, we determined the genomic changes in the X, S, basal core promoter (BCP), and precore regions of HBV, and evaluate their role in the development of HCC in chronic hepatitis B (CHB) patients with genotype C HBV. As the results, it was suggested that T1753V mutation in X region might significantly increase the risk of HCC development in CHB patients with genotype C HBV. Also, the BCP mutations might act in synergy with T1753V or G1896A mutation, and with pre-S deletion to promote the development of HCC in these patients.

Lee D, Lyu H, Chung YH, Kim JA, Mathews P, Jaffee E, Zheng L, Yu E, Lee YJ, Ryu SH. Genomic changes in hepatitis B virus associated with development of hepatocellular carcinoma. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

Worldwide, hepatocellular carcinoma (HCC) is one of the most common malignant tumors[1]. One of the major risk factors closely associated with HCC development is chronic hepatitis B virus (HBV) infection, which in combination with the hepatitis C virus accounts for more than 80% of HCC worldwide[2]. The specific details of the hepatocarcinogenesis from the initial HBV infection is still unclear, although it has been suggested that many factors including but not limited to sex, age, viral genotype environmental factors, and genetic susceptibility all play an important role in the multistage process of HCC development[3].

Due to the high degree of genetic heterogeneity of the virus, there may be multiple mechanisms by which HBV causes HCC. Some studies have found that HBV can directly provoke hepatocarcinogenesis through chromosomal integration or transactivation of cellular genes[3,4]. Regardless, many of these molecular changes indirectly or directly leading to the development of HCC can be linked to genomic changes within the virus.

Various mutations in the HBV genome have been strongly associated with the development of HCC. A significant amount of evidence points to specific genetic mutations as essential viral factors contributing to the development of HCC that could serve as important prognostic biomarkers of the disease. The substitution of A by T at nucleotide 1762 (A1762T) and of G by A at nucleotide 1764 (G1764A) in the basal core promoter (BCP) region is the most common mutation in the HBV genome. This BCP mutation has been associated with higher occurrence of HCC[5,6]. In addition, it has been reported that other mutations of HBV such as G to A transition at nucleotide 1896 (G1896A) in the precore (PC) region, substitution from C to T at nucleotide 1653 (C1653T) and from T to either C/A/G at nucleotide 1753 (T1753V) in the X region, and the deletion in the pre-S region, may be associated with HCC, although their exact roles are still unknown[7-12].

Moreover, it has been demonstrated that genotype C HBV is strongly associated with mutations in the core promoter region and these particular mutations have been shown to be independent risk factors for HCC development[6,13,14]. Consequently, those infected with genotype C HBV may have a poorer prognosis with more aggressive liver disease[11].

Individual mutations within the HBV genome have been studied in order to prove their role in HCC development in chronic hepatitis B patients. Nevertheless, combined mutations in the HBV genome must also be recognized to have the potential to serve as predictive markers for HCC due to the potential ability of the virus to acquire mutations over time. Although there are few reports about the effects of combined mutations of HBV on HCC development, these results are still controversial.

Therefore, in this study, we intended to investigate the genomic changes in the X, S, BCP, and PC regions of HBV. And also we aimed to evaluate their roles in the development of HCC in patients chronically infected with genotype C HBV.

**MATERIALS AND METHODS**

***Subjects***

This study included 240 patients with chronic hepatitis B (CHB) diagnosed at Asan Medical Center, Seoul, Korea, between 1991 and 1998. All patients fulfilled the following requirements: (1) seropositivity for hepatitis B surface antigen for at least 6 mo; (2) age > 20 years; and (3) diagnosis with genotype C HBV. The exclusion criteria were as follows: (1) co-infection with hepatitis C virus, hepatitis D virus or human immunodeficiency virus; or (2) diagnosis with HCC at the time of screening.

The patients were followed up regularly at 3-6 month intervals. Serum biochemistry, hematology, HBV DNA titers, hepatitis B e antigen (HBeAg), and anti-HBe, were obtained at each visit. Serum alpha-fetoprotein (AFP), and imaging studies such as ultrasonography or dynamic computed tomographic scan were also performed for the surveillance of HCC development during follow-up. The diagnosis of HCC was determined using AASLD guidelines requiring typical imaging patterns on dynamic CT scan or MRI or pathologic findings[15]. This study was approved by the Institutional Review Board of Asan Medical Center.

***HBV genotyping and detection of HBV mutations***

HBV DNA was extracted from patient’s serum or liver tissue samples using QIAmp DNA extraction kit (Qiagen K.K., Tokyo, Japan). The HBV genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) of the surface gene of the HBV genome. False positives were avoided by preventing cross-contamination and duplicating the tests in order to validate the results.

The sequence was analyzed by amplifying the entire X, S, PC/core, and BCP regions of the HBV genomes. These regions of HBV genome were then sequenced using a direct sequencing method. The methods used for the genotyping and sequencing of the HBV genome were detailed in our previous study[6]. The sequencing conditions, including A1762T or G1764A in the BCP region, G1896A in the PC region, C1653T or T1753V in the region encoding HBx, and the pre-S deletion mutation were specified in the protocol for the Taq DyeDeoxy Terminator Cycle Sequencing Kit (ABI).

***Statistical analysis***

All variables are expressed as the median (range) or number (percentage). Follow-up duration was calculated from the date of enrollment to the last visit and time to recurrence was defined as the duration from enrollment to HCC diagnosis. To identify factors predisposing the development of HCC, the Kaplan-Meier method and log-rank test were used. And also multivariate analysis was performed using the Cox proportional hazards model. All significance tests were two-tailed, and *P* < 0.05 was considered to be statistically significant. All statistical analyses were performed using the SPSS statistical software package (version 20; SPSS Inc., Chicago, IL).

**RESULTS**

***Baseline characteristics***

The demographic data of the 240 patients with CHB are summarized in Table 1. All of the patients had a genotype C HBV infection. About 84% of the patients were male and the median age was 48 years (range, 27-86 years). More than 90% of the patients had relatively well-preserved liver function with Child-Pugh Class A and the median serum alanine aminotransferase (ALT) level was 149 IU/L (range, 10-2170 IU/L). Over 80% of the study subjects were positive for HBeAg. The median follow-up period was 105 mo (range, 1-237 mo).

***Prevalence of HBV genomic mutations in CHB patients***

The frequencies of genomic mutations in HBV are shown in Figure 1. The C1653T mutation in the X region was found in 10% of the study cases (*n* = 25). Another mutation in the X region, T1753V, was seen in 14% (*n* = 33). The BCP double mutation, A1762T/G1764A was detected in 65% (*n* = 157). The G1896A mutation in the PC region was seen in 21% (*n* = 50) and the pre-S deletion was found in 28% (*n* = 67).

***Overall occurrence rates of HCC in CHB patients***

During follow-up, 6 of 240 patients with CHB (3%) newly developed HCC. The 5-, 10-, and 15-year overall cumulative occurrence rates of HCC were 0%, 1.8% and 4.1%, respectively (Figure 2).

***Development of HCC in relation to individual genomic mutations in HBV***

The presence of the T1753V mutation in the X region was significantly associated with the development of HCC (Figure 3). The 10- and 15-year cumulative occurrence rates of HCC were 5% and 19%, respectively, in patients with the T1753V mutation, which were significantly higher than the 1% 10- and 15-year rates seenin those with wild-type HBV (*P* < 0.001). However, other point mutations, such as C1653T in the X region, the BCP double mutation A1762T/G1764A, G1896A in the PC region, and the pre-S deletion, did not affect HCC occurrence (Table 2).

***Effects of combined mutations in HBV genome on HCC development***

The occurrence rates of HCC were assessed in relation to the presence of combined mutations to evaluate the synergic effects of genomic changes in HBV. The combination of the BCP double mutations A1762T/G1764A and the T1753V mutation had a close association with HCC development (*P* < 0.01) (Figure 4A). Patients with both BCP A1762T/G1764A mutations and the G1896A mutation also had a significantly higher occurrence rate of HCC (*P* < 0.05) (Figure 4B). In addition, coexistence of BCP double mutations and pre-S deletion showed the higher HCC occurrence rates (*P* < 0.05) (Figure 4C). However, the combination of BCP double mutations and C1653T in the X region was not significantly associated with HCC development (Figure 4D).

***Predisposing factors of the development of HCC in patients with CHB***

The occurrence rates of HCC in relation to baseline characteristics were also evaluated (Table 2). Age and gender did not showed significant association with the occurrence of HCC in univariate analysis. In addition, other clinical characteristics, such as serum ALT level, prothrombin time, serum AFP level, HBeAg positivity, and HBV DNA titers, did not affect HCC development. In multivariate analysis, the presence of the T1753V mutation in the X region was an independent risk factor for the development of HCC (relative risk 14.03, *P* < 0.05) (Table 3).

**DISCUSSION**

The impact of genomic changes in HBV on the clinical course of the infection—from the initial viral infection to HCC development-has been of great interest due to the unclear nature of the relationship between the two components. Our work clarifies some of the uncertainty because our results suggest that patients with the T1753V mutation in the X region of the HBV genome are more likely to develop HCC as a result of their chronic HBV infection, especially that of genotype C. The HBx, a nonstructural regulatory protein of HBV, may play an essential role in hepatocarcinogenesis in the context of HBV. Studies of HBx transgenic mice have provided limited results regarding the role of the X-gene in live tumor formation[3,7,11]. Moreover, the exact role of the genomic mutations in the X region is still unclear. However, the present findings indicated that the T1753V mutation in the X region is an independent risk factor for the development of HCC in patients with CHB. Our results thus suggest that an amino acid change at nucleotide 1753 in the X region can affect the function of the HBx protein and thereby contribute to the process of hepatocarcinogenesis[7,11,16]. Therefore, it seems likely that mutations in the X region resulting in the translation of a truncated HBx protein contribute to the initiation of tumor formation in the liver[3,17].

The BCP double mutation A1762T/G1764A is one of the most common mutations in the HBV genome. The current study also showed high prevalence (65%) of A1762T/G1764A in patients with CHB of genotype C. However, the BCP double mutation was not significantly associated with HCC development. Nevertheless, we found that A1762T/G1764A tended to have high occurrence rates of HCC, although the results were not statistically significant. Interestingly, the BCP double mutation A1762T/G1764A significantly contributed to HCC development when it was combined with other individual mutations such as T1753V in the X region, G1896A in the PC region, or the pre-S deletion. Thus, the BCP mutations may also be associated with hepatocarcinogenesis[13,18]. The BCP mutations may change the viral pre-genomic secondary structure or increase the transcription of the pre-genomic RNA, consequently, the BCP mutations can increase viral replication[14,19].

The PC mutation terminates the translation of HBeAg by creating a premature stop codon in the PC gene[6,7,20]. However, the exact role of this mutation is unclear because, although the mutation has been demonstrated to cause more severe liver disease, it was frequently detected in HBeAg-negative asymptomatic carriers[9,21,22]. In particular, one study has shown that the PC 1896 mutation alone appears to have no direct pathogenic role in HBV genotype C[21]. Our results also showed that the PC G1896A mutation alone was not significantly associated with HCC development, but a combination of the PC mutation and the BCP double mutation significantly influenced HCC occurrence.

Truncated pre-S2/S sequences can often be found in HBV DNA integration sites in HCC[3,23]. As in our present results, a recent study in Taiwan showed that the combination of the pre-S deletion mutation and the BCP double mutation was significantly associated with the development of HCC[6,24]. It is possible that hepatocytes expressing altered large and middle surface proteins encoded by the mutated S gene have a potential growth advantage[10,25]. Moreover, the pre-S mutant has been found to upregulate cyclin A expression and induce nodular proliferation of hepatocytes[10,17]. The modified surface antigen may induce oxidative DNA damage and mutations in hepatocytes in the late stages of a chronic HBV infection[10,26].

One limitation of our present study was the small number of newly developed HCC cases during follow-up. Out of 240 patients with CHB, only 6 patients developed HCC. However, most subjects had CHB, not liver cirrhosis. In addition, the median follow-up duration was about 9 years, which may be insufficient duration for HCC development, especially in patients with CHB. Nevertheless, our current study is one of the largest of its kind to date and had a longer follow-up period than other similar reports.

In conclusion, the presence of the T1753V mutation in the X region significantly increases the risk of HCC development in patients with genotype C CHB. The BCP mutations may act in synergy with the T1753V mutation in the X region, G1896A in the PC region, and with the pre-S deletion to significantly increase the occurrence of HCC in CHB patients with genotype C HBV.

**COMMENTS**

***Background***

Hepatitis B virus (HBV) is the most common risk factor for hepatocellular carcinoma development. Especially, among the various characteristics of HBV, genomic variation of the virus may effect on hepatocellular carcinoma (HCC) development directly. However, the exact role of the genomic mutation of hepatitis B virus is still controversial for hepatocarcinogenesis. Thus, it is very important to clarify obvious function of the genomic mutation for the development of HCC in patients with hepatitis B virus infection.

***Research frontiers***

The authors are part of the leading group in the studies of carcinogenesis for hepatitis B virus associated HCC. The authors believe that some mutations in the basal core promoter, the precore, and the X regions may be associated with HCC development. We provide reasonable evidence to support the hypothesis which we have made from this paper.

***Innovations and breakthroughs***

Generally agreed by the most researchers on genomic changes of hepatitis B virus are able to effect on the development of HCC. However, their opinions are far from being unanimous as to obvious role of each mutation for the development of HCC. This paper shows that the T1753V mutation in X region plays an important role as the risk factor for HCC development. Moreover, combined mutations of the basal core promoter mutation and other mutations such as T1753V, G1896A, and the pre-S deletion are also the risk factors for the development of HCC in patients with genotype C HBV infection.

***Applications***

High risk group for HCC development can be identified among the patients infected with genotype C hepatitis B virus. Furthermore, we can establish efficient process to detect HCC earlier and also we may prevent the development of HCC ultimately.

***Terminology***

HBV is a member of hepadnaviridae family, and it can cause acute hepatitis, fulminant hepatitis, asymptomatic carrier state, chronic hepatitis, cirrhosis, and HCC. Especially, HBV is the most common risk factor for HCC development. Because HBV has the high degree of genetic diversity, it is considered that the genomic changes of HBV can influence on the carcinogenesis of HCC, although the exact role of each genomic mutation is not obvious. HCC is a primary cancer of the liver and usually occurs in patients with chronic liver disease, especially chronic hepatitis B. Multiple mechanisms impact on the development of HCC and some of mechanisms has not been fully verified as yet.

***Peer-review***

Excellent study has been performed by Danbi Lee *et al* reporting about the association between genomic changes of genotype C HBV and HCC development. This study definitely help to verify mechanism of HCC development. Congratulation to authors for the valuable results for role of genetic mutation of HBV for the hepatocarcinogenesis.

**REFERENCES**

1 **van Zonneveld M**, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. *Hepatology* 2004; **39**: 804-810 [PMID: 14999700 DOI: 10.1002/hep.20128]

2 **Nguyen VT**, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. *J Viral Hepat* 2009; **16**: 453-463 [PMID: 19302335 DOI: 10.1111/j.1365-2893.2009.01117.x]

3 **Park NH**, Song IH, Chung YH. Chronic hepatitis B in hepatocarcinogenesis. *Postgrad Med J* 2006; **82**: 507-515 [PMID: 16891440 DOI: 10.1136/pgmj.2006.047431]

4 **Pang R**, Tse E, Poon RT. Molecular pathways in hepatocellular carcinoma. *Cancer Lett* 2006; **240**: 157-169 [PMID: 16239065 DOI: 10.1016/j.canlet.2005.08.031]

5 **Kao JH**, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. *Gastroenterology* 2003; **124**: 327-334 [PMID: 12557138 DOI: 10.1053/gast.2003.50053]

6 **Lyu H**, Lee D, Chung YH, Kim JA, Lee JH, Jin YJ, Park W, Mathews P, Jaffee E, Zheng L, Yu E, Lee YJ. Synergistic effects of A1896, T1653 and T1762/A1764 mutations in genotype c2 hepatitis B virus on development of hepatocellular carcinoma. *J Viral Hepat* 2013; **20**: 219-224 [PMID: 23383661 DOI: 10.1111/j.1365-2893.2012.01654.x]

7 **Asim M,** Malik A, Sarma MP, Polipalli SK, Begum N, Ahmad I, Khan LA, Husain SA, Akhtar N, Husain S, Thayumanavan L, Singla R, Kar P. Hepatitis B virus BCP, Precore/core, X gene mutations/genotypes and the risk of hepatocellular carcinoma in India. *J Med Virol* 2010; **82**: 1115-1125 [PMID: 20513073 DOI: 10.1002/jmv.21774]

8 **Omata M**, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. *N Engl J Med* 1991; **324**: 1699-1704 [PMID: 2034246 DOI: 10.1056/NEJM199106133242404]

9 **Okamoto H**, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. *J Virol* 1990; **64**: 1298-1303 [PMID: 2304145]

10 **Fang ZL**, Sabin CA, Dong BQ, Wei SC, Chen QY, Fang KX, Yang JY, Huang J, Wang XY, Harrison TJ. Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study. *J Gen Virol* 2008; **89**: 2882-2890 [PMID: 18931087 DOI: 10.1099/vir.0.2008/002824-0]

11 **Shinkai N**, Tanaka Y, Ito K, Mukaide M, Hasegawa I, Asahina Y, Izumi N, Yatsuhashi H, Orito E, Joh T, Mizokami M. Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. *J Clin Microbiol* 2007; **45**: 3191-3197 [PMID: 17652471 DOI: 10.1128/JCM.00411-07]

12 **Chen BF**, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. *Gastroenterology* 2006; **130**: 1153-1168 [PMID: 16618410 DOI: 10.1053/j.gastro.2006.01.011]

13 **Yuen MF**, Sablon E, Tanaka Y, Kato T, Mizokami M, Doutreloigne J, Yuan HJ, Wong DK, Sum SM, Lai CL. Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. *J Hepatol* 2004; **41**: 119-125 [PMID: 15246217 DOI: 10.1016/j.jhep.2004.03.004]

14 **Yuen MF**, Tanaka Y, Shinkai N, Poon RT, But DY, Fong DY, Fung J, Wong DK, Yuen JC, Mizokami M, Lai CL. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. *Gut* 2008; **57**: 98-102 [PMID: 17483190 DOI: 10.1136/gut.2007.119859]

15 **Bruix J**, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; **53**: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]

16 **Takahashi K**, Ohta Y, Kanai K, Akahane Y, Iwasa Y, Hino K, Ohno N, Yoshizawa H, Mishiro S. Clinical implications of mutations C-to-T1653 and T-to-C/A/G1753 of hepatitis B virus genotype C genome in chronic liver disease. *Arch Virol* 1999; **144**: 1299-1308 [PMID: 10481738]

17 **Wang Y**, Lau SH, Sham JS, Wu MC, Wang T, Guan XY. Characterization of HBV integrants in 14 hepatocellular carcinomas: association of truncated X gene and hepatocellular carcinogenesis. *Oncogene* 2004; **23**: 142-148 [PMID: 14712219 DOI: 10.1038/sj.onc.1206889]

18 **Chu CM**, Lin CC, Lin SM, Lin DY, Liaw YF. Viral load, genotypes, and mutants in hepatitis B virus-related hepatocellular carcinoma: special emphasis on patients with early hepatocellular carcinoma. *Dig Dis Sci* 2012; **57**: 232-238 [PMID: 21837473 DOI: 10.1007/s10620-011-1844-2]

19 **Kidd AH**, Kidd-Ljunggren K. A revised secondary structure model for the 3'-end of hepatitis B virus pregenomic RNA. *Nucleic Acids Res* 1996; **24**: 3295-3301 [PMID: 8811080]

20 **Yotsuyanagi H**, Hino K, Tomita E, Toyoda J, Yasuda K, Iino S. Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. *J Hepatol* 2002; **37**: 355-363 [PMID: 12175631]

21 **Yoo BC**, Park JW, Kim HJ, Lee DH, Cha YJ, Park SM. Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea. *J Hepatol* 2003; **38**: 98-103 [PMID: 12480566]

22 **Baptista M**, Kramvis A, Kew MC. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. *Hepatology* 1999; **29**: 946-953 [PMID: 10051502 DOI: 10.1002/hep.510290336]

23 **Bréchot C**. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. *Gastroenterology* 2004; **127**: S56-S61 [PMID: 15508104]

24 **Chen CH**, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, Lu SN, Changchien CS. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. *Gastroenterology* 2007; **133**: 1466-1474 [PMID: 17915220 DOI: 10.1053/j.gastro.2007.09.002]

25 **Fan YF**, Lu CC, Chang YC, Chang TT, Lin PW, Lei HY, Su IJ. Identification of a pre-S2 mutant in hepatocytes expressing a novel marginal pattern of surface antigen in advanced diseases of chronic hepatitis B virus infection. *J Gastroenterol Hepatol* 2000; **15**: 519-528 [PMID: 10847439]

26 **Hsieh YH**, Su IJ, Wang HC, Chang WW, Lei HY, Lai MD, Chang WT, Huang W. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. *Carcinogenesis* 2004; **25**: 2023-2032 [PMID: 15180947 DOI: 10.1093/carcin/bgh207]

**P-Reviewer:** Liu EQ, Qin JM **S-Editor:** Qi Y **L-Editor: E-Editor:**



**Figure 1 Prevalence of genomic changes in genotype C hepatitis B virus.**

**Figure 2 Overall occurrence rates of hepatocellular carcinoma in chronic hepatitis B patients with genotype C hepatitis B virus.**



**Figure 3 Cumulative occurrence rates of hepatocellular carcinoma in relation to the T1753V mutation in the X region.**









**Figure 4 Cumulative occurrence rates of hepatocellular carcinoma in relation to the combination.** A: The BCP A1762T/G1764A double mutation and with the T1753V mutation in the X region; B: The BCP A1762T/G1764A double mutation and the G1896A mutation in the PC region; C: The BCP A1762T/G1764A double mutation and the pre-S Deletion; D: The BCP A1762T/G1764A double mutation and the C1653T mutation in the X region.

**Table 1 Baseline characteristics of patients with chronic hepatitis B** ***n* (%)**

|  |  |
| --- | --- |
| **Variables** | ***n* = 240** |
| Age, yr1 | 48 (27-86) |
| Gender, M/F | 201/39 (84/16) |
| 1Platelet, × 103/mm3 | 176 (62-556) |
| Prothrombin time, %1 | 87 (30-147) |
| ALT, IU/L1 | 149 (10-2170) |
| Total bilirubin, mg/dL1 | 0.8 (0.3-15.4) |
| Albumin, g/dL1 | 4.1 (2.2-5.2) |
| Serum AFP, ng/mL1 | 5.9 (1-2150) |
| Child-Pugh class, A/B/C | 216/15/0 (94/6/0) |
| HBeAg positivity | 195 (81) |
| Serum HBV DNA, copies/mL1 | 4.2 × 106 (ND-1.1 × 109)  |
| Presence of HBV genotype C | 240 (100) |
| Follow-up periods, mo1 | 105 (1-237) |

1Median (range). ALT: Alanine aminotransferase; AFP: α-fetoprotein; HBeAg: Hepatitis B e antigen; ND: Not-detected.

**Table 2 Univariate analysis of risk factors for hepatocellular carcinoma development**

|  |  |  |
| --- | --- | --- |
| **Variables** | **RR (95%CI)** | ***P* value** |
| **Genomic changes** |  |  |
| C1653T in X region | 1.583 (0.176 - 14.210) | NS |
| T1753V in X region | 17.565 (1.956 - 157.737) | < 0.01 |
| A1762T/G1764A in BCP | 30.512 (0.004 - 230706) | NS |
| G1896A in PC | 5.765 (0.519 - 64.076)  | NS |
| Pre-S deletion | 2.491 (0.502 - 12.370) | NS |
|  |  |  |
| **Clinical characteristics** |  |  |
| Age > 50 yr | 57.5 (0.035 – 93428) | NS |
| Male | 27.3 (0.001 – 547718) | NS |
| ALT > 80 IU/L | 0.55 (0.091 – 3.29) | NS |
| PT ≤ 70 % | 4.12 (0.682 – 24.845) | NS |
| Serum AFP > 200 ng/mL | 0.044 (0.00 – 209046) | NS |
| HBeAg positive | 0.034 (0.00 – 360.724) | NS |
| HBV DNA > 105 copies/mL | 0.741 (0.123 – 4.452) | NS |

RR: Relative risk; CI: Confidence interval; NS: Not significant; BCP: Basal core promoter; PC: Precore; ALT: Alanine aminotransferase; PT: Prothrombin time; AFP: α-fetoprotein; HBeAg: Hepatitis B e antigen.

**Table 3 Multivariate analysis of predisposing factors for hepatocellular carcinoma development**

|  |  |  |
| --- | --- | --- |
| **Variables** | **RR (95%CI)** | ***P* value** |
| Age > 50 yr | 102903 (.000 - 1838) | NS |
| Male | 196796 (.000 - 2834) | NS |
| T1753V in X region | 14.029 (1.568 - 125.550) | < 0.05 |

NS: Not significant.